Factors influencing the treatment response of Cyclosporine-A therapy in aplastic anemia patients in resource-limited settings

Sammy Samuel Bartimeus Kardinan; Andi Fachruddin Benyamin; Muhammad Ilyas; Syakib Bakri; Suriani Alimuddin; Arifin Seweng

doi:10.23750/abm.2026.18530

Factors influencing the treatment response of Cyclosporine-A therapy in aplastic anemia patients in resource-limited settings

Authors

Sammy Samuel Bartimeus Kardinan Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0009-0004-3394-7265
Andi Fachruddin Benyamin Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0003-1811-0497
Muhammad Ilyas Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0002-3927-651X
Syakib Bakri Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0002-6615-5166
Suriani Alimuddin Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0001-8996-3994
Arifin Seweng Department of Public Health and Community Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0003-0853-7809

Keywords:

Aplastic Anemia, Cyclosporine-A, Immunosuppresive Therapy, Prognostic Factors, Resource-Limited Settings

Abstract

Background and aim: Cyclosporine-A (CsA) is the preferred treatment for Aplastic Anemia (AA) in developing countries with restricted access to Antithymocyte Globulin (ATG) and Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD HSCT). Treatment response to CsA is variable, and this study aims to determine the factors influencing the treatment response of CsA in AA patients.

Methods: A cross-sectional analytical observational study included 40 AA patients diagnosed according to Camitta criteria, who had CsA therapy for 3 months at the Hematology-Oncology Outpatient Clinic at Wahidin-Sudirohusodo Hospital, Indonesia, from June 2023 to June 2025. The treatment response was evaluated using the British Society for Haematology’s 2024 Guideline. The examined factors comprised age, body mass index (BMI), diagnosis-to-treatment interval, number of blood transfusions preceding therapy, corticosteroid administration, comorbidities (hypertension and diabetes mellitus), and disease severity. Multivariate logistic regression analysis was used to identify variables influencing CsA treatment response.

Results: This study reported a 40% response rate (RR) to CsA therapy (27.5% partial response and 12.5% complete response). A significant correlation was identified between the number of blood transfusions preceding therapy (P = 0.022; OR = 7.328; CI 1.341-40.056) and disease severity (P = 0.040; OR = 12.081; CI 1.122-130.054) concerning CsA treatment response within 3 months.

Conclusions: Our findings suggest that AA patients who received ≥3 blood transfusions preceding therapy and exhibited severe disease were less likely to respond to CsA therapy. This highlights the prognostic importance of transfusion history and disease severity in predicting treatment outcomes.

References

1. Widjanarko A, Sudoyo AW, Salonder H. Anemia aplastik. In: Buku ajar ilmu penyakit dalam. Jilid VII. Jakarta: Interna Publishing; 2024. p. 3178-87.

2. Nimmana BK, Penney SW. Aplastic anemia [updated 2025 Jul 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. [cited 2025 Dec 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534212

3. Ahmed P, Chaudhry Q, et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology. 2020;25(1):48-54. doi:10.1080/16078454.2019.1711344

4. Rizki A, Rofinda D. Profil penderita anemia aplastik di RSUP Dr. M. Djamil Padang tahun 2018-2019. Indones J Health Sci. 2021;2(1). [cited 2025 Dec 14]. Available from: https://jikesi.fk.unand.ac.id

5. Moore CA, Krishnan K. Aplastic anemia [updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. [cited 2025 Dec 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534212/

6. Al-Ghazaly J, Al-Dubai W, Al-Jahafi AK, et al. Cyclosporine monotherapy for severe aplastic anemia: a developing country experience. Ann Saudi Med. 2015;25(5):375-9. doi:10.5144/0256-4947.2005.375

7. Matsuda K, Koya J, Arai S, Nakazaki K, Nakamura F, Kurokawa M. Cyclosporine therapy in patients with transfusion-independent non-severe aplastic anemia: a retrospective analysis. Intern Med. 2019;58(3):355-60. doi:10.2169/internalmedicine.1372-18.

8. Mandal PK, Baul S, Dolai TK, De R, Chakrabarti P. Outcome of cyclosporine monotherapy in patients of aplastic anemia: experience of a tertiary care hospital in eastern India. Indian J Hematol Blood Transfus. 2017;33(1):144-7. doi:10.1007/s12288-016-0706-7.

9. Li H, Fu L, Yang B, Chen H, Ma J, Wu R. Cyclosporine monotherapy in patients with non-severe aplastic anemia: a retrospective analysis. Front Med (Lausanne). 2022; 9:805197. doi:10.3389/fmed.2022.805197.

10. Awan MN, Shahbaz N, Hidayat I, Kerio AA, Khan H, Siddiq A. Response to single agent cyclosporin in patients with non-severe aplastic anaemia. J Coll Physicians Surg Pak. 2024;34(9):1056-60. doi:10.29271/jcpsp.2024.09.1056. PMID: 39262005.

11. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. Br J Haematol. 2024;204(3):784-804. doi:10.1111/bjh.19236.

12. Wang J, Shen P, Wu X, Jin W. Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: a meta-analysis of retrospective studies. Exp Ther Med. 2020;19(4):3104-12. doi:10.3892/etm.2020.8536. PMID: 32256799; PMCID: PMC7086236.

13. Walter J, Rolles B, Schumacher Y, et al. Analysis of the impact of body mass index (BMI) on the durability of response in patients with aplastic anemia treated with weight-adjusted horse anti-thymocyte globulin (hATG). Blood. 2023;142(Suppl 1):5641. doi:10.1182/blood-2023-183075.

14. Somprasertkul T, Trirattanapikul W, et al. Treatment response and its predictors of immunosuppressive therapy in patients with severe or very severe aplastic anemia. Med Drug Discov. 2024; 22:100181. doi: 10.1016/j.medidd.2024.100181.

15. Antonio MR, Iacobelli S, Kulasekararaj AG, et al. Eltrombopag added to standard immunosuppressive treatment improves long-term outcomes as front-line therapy for severe aplastic anemia: final 2-year analysis of EBMT-SAAWP RACE study. Blood. 2024;144(Suppl 1):302. doi:10.1182/blood-2024-194699.

16. Nakamura R, Patel BA, Kim S, Wong FL, Armenian SH, Groarke EM, Keesler DA, Hebert KM, Heim M, Eapen M, Young NS. Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy. Haematologica. 2023;108(12):3298-307. doi:10.3324/haematol.2023.282781.

17. Leyu W, Ye L, Zhao X, Chen M, Zhang F, Han B. Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study. Blood Cancer J. 2025;15(1):119. doi:10.1038/s41408-025-01328-3. PMID: 40617806; PMCID: PMC12228700.

18. Julen K, Volken T, Holbro A, et al. Transfusions in aplastic anemia patients cause HLA alloimmunization: comparisons of current and past cohorts demonstrate progress. Transplant Cell Ther. 2021;27(11):939.e1-939.e8. doi: 10.1016/j.jtct.2021.07.017.

19. Wirk B. Acquired aplastic anemia therapies: immunosuppressive therapy versus alternative donor hematopoietic cell transplantation. J Hematol. 2024;13(3):61-70. doi:10.14740/jh1264. PMID: 38993743; PMCID: PMC11236356.

20. Yawen Z, Yao H, Suli W, et al. Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic. Front Immunol. 2023; 14:1197982. doi:10.3389/fimmu.2023.1197982.

21. Piekarska A, Pawelec K, Szmigielska-Kapłon A, Ussowicz M. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol. 2024; 15:1378432. doi:10.3389/fimmu.2024.1378432.

22. Young NS. Aplastic anemia. In: Longo DL, editor. N Engl J Med. 2018;379(17):1643-56. doi:10.1056/NEJMra1413485.

23. Prabahran A, Durrani J, Coelho-Da Silva J, Shalhoub R, Lotter J, Rios O, Ritchie DS, Wu CO, Patel BA, Young NS, Groarke EM. Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. Br J Haematol. 2024;205(3):1170-9. doi:10.1111/bjh.19648. PMID: 39021060; PMCID: PMC11499006.

24. Yu J, Wei X, Gao J, et al. Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity. Toxicol. 2023; 492:153544. doi: 10.1016/j.tox.2023.153544.

25. Fadini GP, Albiero M. Impaired haematopoietic stem/progenitor cell traffic and multi-organ damage in diabetes. Stem Cells. 2022;40: sxac035. doi:10.1093/stmcls/sxac035.

26. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-36. doi:10.1182/blood-2016-08-693481.

27. Liu J, Lu XY, Cheng L, Yang Y, Lin SY, Yin H, Liu XQ, Wu XM, He GS. Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with absolute neutrophil count of zero. Hematology. 2019;24(1):492-7. doi:10.1080/16078454.2019.1631424. PMID: 31221029.

28. Groarke EM, Durrani J, Chen LN, Shalhoub RN, Baez V, Glass J, et al. Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy. Blood Adv. 2025;9(11):2639 2650. doi:10.1182/bloodadvances.2024015301